KMKarolina Maliszewska

Karolina Maliszewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karolina Maliszewska has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Co-existence of mental disorders in patients with epilepsy – literature review

    by Maciej Kwieciński, Karolina Gendek-Łapińska, Julia Ścibior, Karolina Maliszewska, Weronika Ziomek, Dawid Suwała

    Introduction and objective: Epilepsy has a significant impact on patients’ psychiatric condition. Epidemiological studies have shown that comorbid psychiatric disorders can occur in about 20–40% of patients with epilepsy. The aim of th study is to raise awareness of how much...

  • Semaglutide – a long – awaited cure for obesity or an elusive treatment?

    by Izabela Oleksak, Karolina Maliszewska, Tomasz Szawłoga, Iwona Welian-Polus, Kraków Specialist Hospital Named After Ludwik Rydygier In Kraków, Wiktoria Wilanowska, Lublin Stefan Kardynał Wyszyński Province Specialist Hospital in Lublin, Kamila Babkiewicz-Jahn, Justyna Matuszewska, Adrianna Szymańska

    Introduction and aim. Obesity is a challenging disease that affects various organs and cannot be easily treated. Therefore, the discovery that taking semaglutide results in weight loss caused great excitement amongst patients and medical professionals. The aim of this literature review is to explore the benefits and dangers of semaglutide and its effectiveness in treating obesity. Material and methods. Review of articles published in PubMed since 2017 until first quarter of 2024. Analysis of literature. Obesity is an increasing problem of the world population. There are different approaches in obesity treatment. Semaglutide seems effective in treating diabetes, as well as conditions that emerge from long-lasting obesity. It showed positive influence regarding diabetic neuropathy, cardiovascular risk and more. It is important to remember about possible adverse events. The most prominent are gastrointestinal symptoms, such as nausea, diarrhea, vomiting, and abdominal pain. New reports show complications with simultaneous use of anesthesia or coexisting depression. Larger studies on semaglutiderelated side effects will be published in 2025 and in 2026. Conclusion. Semaglutide is an anti-diabetic drug showing promising effects in treating diabetes and in alleviating conditions caused by obesity. It is worth remembering that its side effects have not yet been fully investigated.

  • Open Access

    Role of nutrition in cerebral palsy treatment – comprehensive literature review

    by Iwona Welian-Polus, Michał Leśniewski, Karolina Maliszewska, Izabela Oleksak, Joanna Ziółkowska, Bartosz Mazur, Karolina Gendek, Mikołaj Smach, Magdalena Mazur, Wiktoria Wilanowska

    Introduction and purpose: A collection of symptoms known as cerebral palsy first manifest in early childhood and result in profound physical impairment. Cerebral palsy is thought to affect 1 in 500 live births, or roughly 17 million people worldwide. The type of cerebral palsy determines the clinical symptoms. Movement coordination disorders, epilepsy, muscle weakness, and feeding difficulties are the most common symptoms. The purpose of this article is to familiarize readers with the options for nutritional therapy for cerebral palsy patients. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included cerebral palsy; nutrition; treatment; gut microbiota.. State of knowledge Early identification of malnutrition symptoms and appropriate interventions, such as the implantation of a percutaneous endoscopic gastrostomy tube in patients who are unable to swallow food, are the cornerstones of nutritional therapy for cerebral palsy patients. Dysphagia is a major problem in the population of patients with cerebral palsy, and multidisciplinary therapy is necessary for them. Patients' serum vitamin D levels are also influenced by their diet; 50% of those with cerebral palsy have a deficiency in this nutrient. Conclusions For people with cerebral palsy, nutrition is very important. Premature death may arise from malnutrition brought on by the disease's advancement. As a result, individuals with cerebral palsy need to receive specialized care


  • Open Access

    Diagnostic and therapeutic process of respiratory disorders during sleep

    by Karolina Maliszewska, Izabela Oleksak, Iwona Welian-Polus, Karolina Gendek, Wiktoria Wilanowska, Kamila Babkiewicz-Jahn, Justyna Matuszewska

    Introduction and purpose Sleep apnea is a disturbance of sleep that affects about 10% of adult population and is not easily detected due to unspecific symptoms. The aim of this literature review is to present, respectively, obstructive sleep apnea and central sleep apnea symptoms and integrate the available data in the literature regarding the pathogenesis and treatment methods. Materials and methods A review of literature was performed using PubMed and Google Scholar database. The search criteria included keywords such as sleep apnea, obstructive sleep apnea treatment, central sleep apnea treatment. State of knowledge Sleep disturbances that involve breathing can be categorized as obstructive sleep apnea (OSA) and central sleep apnea. First one is associated with the obstruction of the upper airways and the second one – with malfunctioning breathing generator in the pontomedullary breathing pacemaker. Symptoms are unspecific which makes diagnostic process difficult. However, the right diagnosis and treatment may prevent patients from developing many cardiovascular diseases. Treatment options for OSA include: CPAP, reducing body weight, changing sleep position, braces and surgeries; for CSA: CPAP and acetazolamide. Conclusions OSA and CSA need to be further investigated in order to find more precise ways of diagnosis and treatment, as these diseases remain underreported. It is worth noting, that these conditions predispose to serious diseases, e.g. stroke. Therefore, developing new treatment techniques would beneficial for the health of population.

  • Open Access

    Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan

    by Kamila Babkiewicz-Jahn, Justyna Matuszewska, Adrianna Szymańska, Wiktoria Wilanowska, Izabela Oleksak, Karolina Maliszewska, Natalia Załęska

    Introduction and purpose Heart failure has become a civilization disease, affecting 1-2% of the world's population. It is a condition with various etiologies and phenotypes. The annual mortality rate due to heart failure is approximately 10%, with organ dysfunction caused by hypoperfusion and sudden cardiac death being the leading causes of death. The aim of this study is to present current knowledge of heart failure, focusing on its pathophysiology, and the mechanism of action and applications of sacubitril/valsartan. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included pathophysiology of heart failure; natriuretic peptide pathways; treatment of heart failure; sacubitril/valsartan. Conclusions Heart failure is a syndrome marked by the activation of various neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS) and natriuretic peptides (NP). Historically, the therapeutic approach has focused on reducing RAAS activity and SNS activity. In recent years, increasing attention has been given to potential benefits associated with the NP system. Following disappointing outcomes from studies involving neprilysin (NEP) inhibitors, administered alone or in conjunction with an ACE inhibitor and vasopeptidase inhibitors, there have been findings with the pharmacological class termed ARNI (angiotensin receptor and NEP inhibitors). Sacubitril/valsartan has proven to be an effective and safe treatment that reduces the need for hospitalization, enhances the quality of life and longevity of patients with chronic HFrEF.


  • Open Access

    Diagnostic problems of unusal somatic disorder - Munchausen syndrome by proxy

    by Justyna Matuszewska, Kamila Babkiewicz-Jahn, Adrianna Szymańska, Wiktoria Wilanowska, Izabela Oleksak, Karolina Maliszewska, Natalia Załęska

    Introduction and purpose Munchausen syndrome by proxy is a factitious disorder characterized by the search for and induction of somatic symptoms, the falsification of laboratory results, and even the mutilation of a loved one, usually a child, by a parent or caregiver. Paediatricians often only have information about the child's condition from an interview with the child’s guardian, so it is very important to differentiate feigned disorders from real, sometimes difficult to diagnose, cases of illness. We may suspect them if the parent reports unusual symptoms in the child, insinuates further treatments and hospital stays, has above-average knowledge of medical terminology, and is aggressive towards the staff. Prominent among the causes of Munchausen syndrome by proxy are first and foremost the desire to focus the parent/carer’s attention on themselves and the expectation of recognition for their care and concern for the child. Methods and materials The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included munchausen syndrome, munchausen syndrome by proxy, treatment, diagnosis, paediatric condition falsification, factitious disorder. Conclusions Due to the nature of this disorder, physicians of different specialities may come across it during their practice. Increasing their knowledge on this topic and the effects of Munchausen syndrome by proxy will allow the correct diagnosis to be established and appropriate psychiatric therapy with psychological care to be introduced, as well as protecting children who are victims of the actions of their caregivers.


  • Open Access

    Diagnostic and therapeutic process of neurofibromatosis type 1 and type 2

    by Michał Leśniewski, Iwona Welian-Polus, Izabela Oleksak, Karolina Maliszewska

    Neurofibromatosis is one of the most common genetic diseases. It is inherited in an autosomal dominant manner. It is divided into two genetically distinct subtypes, characterised by multiple skin lesions and tumours of the peripheral and central nervous system. Neurofibromatosis type 1, or Recklinghausen's disease, is the most common phakomatosis. The disease is genetically determined by a mutation of the neurofibromin- 1 gene on chromosome 17. Neurofibromatosis type 2 accounts for 3% of all cases. The disease is genetically determined - caused by a mutation of the neurofibromin-2 gene on chromosome 22. The diagnostic and therapeutic process of neurofibromatosis is a major challenge for clinicians. Given the complexity of the problem, we have reviewed the literature on the diagnostic and therapeutic possibilities of the disease.


  • Open Access

    Does gut microbiota have an impact on the origin of Alzheimer's and Parkinson's disease? – literature review

    by Izabela Oleksak, Michał Leśniewski, Iwona Welian-Polus, Karolina Maliszewska, Joanna Ziółkowska

    Introduction and purpose: Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s disease; gut microbiota; neurodegenerative diseases. State of knowledge The advancement of neurodegenerative processes is linked to the varying progressive course of both disorders. There are numerous likely reasons that connect the development of AD and PD and the gut microbiome. These include the hypotheses on inflammation, the decrease in the quantity of bacteria that produce short-chain fatty acids, and hygiene. The researchers' suggested treatment plans for the two illnesses are comparable. Conclusions A major influence on the development of neurodegenerative disorders is the gut microbiome. To clarify the precise connections between the gut microbiota and the development of AD and PD, further thorough research is required. More human research is required. Furthermore, it's possible that early interventions, such switching to a Mediterranean diet, are anticipated to lower the risk of AD or PD.


  • Open Access

    SMA Therapy in Poland: New Hopes and Challenges

    by Iwona Welian, Karolina Gendek, Ilona Jastrzębska, Karolina Maliszewska, Magdalena Chrościńska-Krawczyk

    Spinal muscular atrophy (SMA) is a genetically inherited disease whose symptoms appear in children at a fairly early age. The main cause of the disease is a mutation of the SMN1 gene, which causes the lack of production of SMN This results in the disappearance of motoneurons, which consequently leads to the disappearance of the patient's ability to move and his death. An important element of coping with the disease is its early detection in newborn screening, because the earlier we start the drug, the greater the chance that the patient will maintain motor efficiency. The article describes treatment options for children in Poland, i. e. the use of such drugs as Nusinersen, which increases the amount of SMN protein, gene therapy Onasemnogen aeparvovec, which increases the amount of SMN gene, Ridisplam, which increases the amount of SMN protein, and salbutamol, which helps patients to breathe. The article also provides information about new drug therapies for the treatment of SMA and the stage of clinical trials at which they are currently being developed. It is important to look for new solutions in the treatment of SMA. Objective: To familiarize the readers of the article with the problems of SMA treatment in Poland, as well as to broaden their knowledge of new available drugs for the treatment of this disease.


  • Open Access

    CAR-T cell therapy – mechanism of action, potential use and limitations a newkind of immunotherapy

    by Karolina Maliszewska, Izabela Oleksak, Agnieszka Kaczmarska, Krystian Cholewa, Adrianna Gorecka, Agata Filip